Neda Slade
Neda Slade
Verified email at irb.hr
Title
Cited by
Cited by
Year
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
AP Grollman, S Shibutani, M Moriya, F Miller, L Wu, U Moll, N Suzuki, ...
Proceedings of the National Academy of Sciences 104 (29), 12129-12134, 2007
6092007
p63 and p73: Roles in Development and Tumor Formation11National Cancer Institute.
UM Moll, N Slade
Molecular cancer research 2 (7), 371-386, 2004
5912004
ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors
AI Zaika, N Slade, SH Erster, C Sansome, TW Joseph, M Pearl, E Chalas, ...
The Journal of experimental medicine 196 (6), 765-780, 2002
4222002
Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid
B Jelaković, S Karanović, I Vuković-Lela, F Miller, KL Edwards, J Nikolić, ...
Kidney international 81 (6), 559-567, 2012
1962012
Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo
N Concin, K Becker, N Slade, S Erster, E Mueller-Holzner, H Ulmer, ...
Cancer research 64 (7), 2449-2460, 2004
1952004
TP53 Mutational signature for aristolochic acid: an environmental carcinogen
M Moriya, N Slade, B Brdar, Z Medverec, K Tomic, B Jelaković, L Wu, ...
International journal of cancer 129 (6), 1532-1536, 2011
1082011
Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer
G Hofstetter, A Berger, H Fiegl, N Slade, A Zorić, B Holzer, E Schuster, ...
Oncogene 29 (13), 1997-2004, 2010
812010
Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival
S Kapitanović, S Radošević, N Slade, M Kapitanović, Š Anđelinović, ...
Journal of cancer research and clinical oncology 126 (4), 205-211, 2000
642000
p53 mutations as fingerprints for aristolochic acid–an environmental carcinogen in endemic (Balkan) nephropathy
N Slade, UM Moll, B Brdar, A Zorić, B Jelaković
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 663 (1 …, 2009
612009
The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease
MJ Jembrek, N Slade, PR Hof, G Šimić
Progress in neurobiology 168, 104-127, 2018
482018
ΔNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation
N Slade, AI Zaika, S Erster, UM Moll
Cell Death & Differentiation 11 (3), 357-360, 2004
482004
Novel Derivatives of Benzo[b]thieno[2,3-c]quinolones:  Synthesis, Photochemical Synthesis, and Antitumor Evaluation
J Dogan Koružnjak, M Grdiša, N Slade, B Zamola, K Pavelić, ...
Journal of medicinal chemistry 46 (21), 4516-4524, 2003
442003
Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers
K Becker, P Pancoska, N Concin, K Vanden Heuvel, N Slade, M Fischer, ...
International journal of oncology 29 (4), 889-902, 2006
422006
Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno [3′, 2′: 4, 5] thieno [2, 3-c] quinolones
J DoganKoruznjak, N Slade, B Zamola, K Pavelic, G Karminski-Zamola
Chemical and pharmaceutical bulletin 50 (5), 656-660, 2002
412002
Arkiv Kemi Arkiv Kemi 16, 563-586, 1960
H Muratake, K Okabe, M Takahashi, M TONEGAWA, M NATSUME, ...
Chemical & pharmaceutical bulletin 45 (5), 799-806, 1997
231997
Mutational Analysis of p53 in Human Tumors
N Slade, UM Moll
p53 Protocols, 231-243, 2003
202003
Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis
A Zorić, A Horvat, N Slade
Carcinogenesis 34 (3), 522-529, 2013
182013
Reduced telomere length is not associated with early signs of vascular aging in young men born after intrauterine growth restriction: a paradox?
M Laganovic, L Bendix, I Rubelj, MV Kirhmajer, N Slade, IV Lela, ...
Journal of hypertension 32 (8), 1613-1620, 2014
162014
Effect of extracellular NADH on human tumor cell proliferation.
N Slade, D Storga-Tomic, GD Birkmayer, K Pavelic, J Pavelic
Anticancer research 19 (6B), 5355-5360, 1999
161999
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
MK Florijan, P Ozretić, M Bujak, L Pezzè, Y Ciribilli, Ž Kaštelan, N Slade, ...
Urologic Oncology: Seminars and Original Investigations 37 (9), 578. e1-578. e10, 2019
122019
The system can't perform the operation now. Try again later.
Articles 1–20